BrainsWay Ltd.
BrainsWay Ltd. (BWAY) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BWAY · as of Jun 8, 2026
Key Statistics
Explore BrainsWay Ltd. Data
bway stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 83.3%
The BWAY analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $16.00, representing +11.15% upside from the current price of $14.39.
Competitors & Peers
bway competitorsBWAY
CERS
CVRX
DCTH
MASS
NPCEStock Performance
Full HistoryAbout BrainsWay Ltd.
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presen…
what is brainsway ltd. · bway stock overview · brainsway ltd. company profile · who is brainsway ltd. ceo · bway NASDAQ · brainsway ltd. headquarters · brainsway ltd. business segments
About Stock Overview & Key Data
BrainsWay Ltd. (BWAY) is a Healthcare company in the Medical - Devices industry, listed on NASDAQ since Apr 17, 2019. As of the latest trading session, BWAY stock price is $14.39, with a market capitalization of $563.2M. The stock has returned +160.62% over the past 12 months and +51.00% year-to-date.
According to 6 Wall Street analysts, the consensus rating for BrainsWay Ltd. stock is Buy, with an average 12-month price target of $16.00. In fiscal year 2025, BrainsWay Ltd. reported revenue of $52.2M and net income of $7.6M. For detailed data — including BrainsWay Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BrainsWay Ltd. (BWAY) stock price is $14.39. The stock is traded on NASDAQ under the ticker symbol BWAY. The 52-week range is $5.11 – $17.35.